News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Atrion (ATRI) Reports Fourth Quarter and Full Year 2011 Results



2/22/2012 7:59:02 AM

ALLEN, TX--(Marketwire - February 21, 2012) - Atrion Corporation (NASDAQ: ATRI) announced today that revenues were down 4% for the fourth quarter but up 8% for the full year 2011 compared to the quarter and year ended December 31, 2010. Revenues for the fourth quarter of 2011 were $25.5 million compared to $26.6 million in the same period of 2010. For the quarter ended December 31, 2011, diluted earnings per share were down 1% compared to the fourth quarter of 2010. For the full year 2011, however, Atrion's revenues increased to $117.7 million from $108.6 million in 2010. Net income per diluted share of $12.82 in 2011 was 24% higher than net income per diluted share of $10.32 in 2010, as described below.

Commenting on the Company's performance for the fourth quarter of 2011 compared to the fourth quarter of 2010, David A. Battat, President & CEO, said, "In the fourth quarter, our financial performance was essentially flat with diluted EPS declining by $0.02 to $2.65. While we experienced an 8% growth in fluid delivery and cardiovascular revenues, areas representing 72% of our overall sales, this good performance was offset by the decline in shipments of ophthalmic products due to the rescheduling of a shipment from late December to January so that a large, multinational customer with which we have a continuing long-term contract, could review its inventory levels."

Mr. Battat also spoke to the full-year results of 2011 compared to 2010 stating, "We are very pleased with the results for the year as a whole as revenues of all major product categories were up, with fluid delivery and cardiovascular increasing 15% and 9% respectively. These excellent results led to an increase in our diluted EPS of 24%." Mr. Battat added, "At year-end our finished goods inventories were up $5.2 million from December 31, 2010. This was due to the postponement of the shipment mentioned above, the need to build safety stocks to mitigate a supplier risk, and to meet contractual obligations to customers. We expect our overall inventory to decline as the year progresses as the shipment and supplier issues are resolved." Mr. Battat added, "As previously announced, last year we embarked on a major program of equipment additions to expand capacity and to continue to raise the quality levels of our products. To that end, we spent $12 million in 2011 as compared to $4 million in 2010. We expect continued high levels of capital additions in 2012, as we complete this phase of modernization. Despite the substantial increase in capital investments last year, our cash and short and long term investments increased by $13.5 million to $55.2 million as of December 31, 2011."

Mr. Battat continued, "Looking forward to 2012, we anticipate that despite the muddled economic outlook in international markets, where we generate 42% of our sales, fluid delivery and cardiovascular revenues will continue to show healthy increases. This month, however, we learned from the above mentioned ophthalmic customer that it had accumulated too large an inventory, necessitating significant reductions in 2012 shipments to it. We expect our earnings for the full year could decline by approximately 10% from 2011 levels. The bulk of this decline will be felt in the first two quarters, which will likely show declines of some 20% before tapering off. While this would mean an interruption of our 13 year history of annual growth in EPS, we wish to emphasize that we believe our business has never been as solidly anchored as it is now and we expect to return to our double-digit growth pattern in 2013."

Atrion Corporation develops and manufactures products primarily for medical applications. The Company's website is www.atrioncorp.com.

Statements in this press release that are forward looking are based upon current expectations and actual results or future events may differ materially. Such statements include, but are not limited to, Atrion's expectations regarding the Company's inventory levels in 2012, a resolution of shipment and supplier issues, capital additions in 2012, fluid delivery and cardiovascular revenues in 2012, earnings for the first two quarters and the full year of 2012, an interruption of our 13 history of double-digit annual growth in EPS in 2012 and a return to the Company's double-digit growth pattern in 2013. Words such as "expects," "believes," "anticipates," "intends," "should", "plans," "will" and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements involve risks and uncertainties. The following are some of the factors that could cause actual results or future events to differ materially from those expressed in or underlying our forward-looking statements: changing economic, market and business conditions; acts of war or terrorism; the effects of governmental regulation; competition and new technologies; slower-than-anticipated introduction of new products or implementation of marketing strategies; the Company's ability to protect its intellectual property; changes in the prices of raw materials; changes in product mix; and intellectual property and product liability claims and product recalls. The foregoing list of factors is not exclusive, and other factors are set forth in the Company's filings with the Securities and Exchange Commission.

ATRION CORPORATION CONSOLIDATED STATEMENTS OF INCOME (In thousands, except per share data) (unaudited) Twelve Months Three Months Ended Ended December 31, December 31, ------------------ ------------------ 2011 2010 2011 2010 -------- -------- -------- -------- Revenues $ 25,519 $ 26,630 $117,704 $108,569 Cost of goods sold 12,815 13,748 57,697 57,655 -------- -------- -------- -------- Gross profit 12,704 12,882 60,007 50,914 Operating expenses 5,073 5,127 21,839 19,937 -------- -------- -------- -------- Operating income 7,631 7,755 38,168 30,977 Interest income 302 320 1,295 1,009 Other income 9 -- 12 2 -------- -------- -------- -------- Income before income taxes 7,942 8,075 39,475 31,988 Income tax provision (2,554) (2,652) (13,437) (11,036) -------- -------- -------- -------- Net income $ 5,388 $ 5,423 $ 26,038 $ 20,952 ======== ======== ======== ======== Income per basic share $ 2.67 $ 2.69 $ 12.90 $ 10.38 ======== ======== ======== ======== Weighted average basic shares outstanding 2,016 2,013 2,019 2,018 ======== ======== ======== ======== $ 2.65 $ 2.67 $ 12.82 $ 10.32 ======== ======== ======== ======== Income per diluted share Weighted average diluted shares outstanding 2,030 2,028 2,031 2,030 ======== ======== ======== ======== ATRION CORPORATION CONSOLIDATED BALANCE SHEETS (In thousands) Dec. 31, Dec. 31, ASSETS 2011 2010 ----------- ----------- (Unaudited) Current assets: Cash and cash equivalents $ 24,590 $ 10,670 Short-term investments 20,279 10,715 ----------- ----------- Total cash and short-term investments 44,869 21,385 Accounts receivable 11,223 11,521 Inventories 24,582 17,400 Prepaid expenses and other 2,313 1,050 Deferred income taxes 755 625 ----------- ----------- Total current assets 83,742 51,981 Long-term investments 10,336 20,291 Property, plant and equipment, net 56,370 50,664 Other assets 11,447 11,716 ----------- ----------- $ 161,895 $ 134,652 =========== =========== LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities 10,043 7,752 Line of credit -- -- Other non-current liabilities 13,338 10,283 Stockholders' equity 138,514 116,617 ----------- ----------- $ 161,895 $ 134,652 =========== ===========


Contact:
Jeffery Strickland
Vice President and Chief Financial Officer
(972) 390-9800



Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES